In a boon for eye care specialist Nicox, the United States Patent and Trademark Office has confirmed that one of its three patents covering a glaucoma treatment could be extended by up to five years.
L’Oreal has secured a victory after a US federal court ruled that the French cosmetics brand did not infringe patents owned by the University of Massachusetts because they were invalid.
Law firm Withers has expanded its US tech practice with the hire of a new team of life sciences and venture capital-focused lawyers in Boston.
Just under a decade ago, Washington became the first state to legalise recreational cannabis, bringing with it the potential to create a legitimate business focused on the buying, selling or distribution of the drug in the US.
Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.
A group of more than 170 former world leaders and Nobel Laureates has called upon US President Joe Biden to waive IP rights for COVID vaccines, in an open letter posted yesterday.
The Fifth Circuit of the Court of Appeals has denied a petition from Impax Laboratories to overturn a decision finding Impax engaged in an illegal pay-for-delay settlement with Endo Pharmaceuticals.
Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.
Repurposing drugs has very clear benefits. It gives companies the opportunity to develop entirely new uses for existing drugs that they don’t have patent protection, and may allow innovator companies to protect a molecule or formulation even after initial patent protection has expired.
Edwards Lifesciences will be able to proceed with its claims of trademark infringement over an artificial heart valve against Meril Life Sciences, according to a US federal court.